NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Rockwell Medical, Inc. RMTI
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$69.3M
▼ 31.8% vs FY2024
EPS · FY25
$-0.15
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-15.3%
Net margin · FY25
-7.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 69.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 8 cents on every revenue dollar this year.
Per share
USD -0.15
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-15.3%
Return on equity, FY2025
ROE
Operating margin-6.8%
Net margin-7.7%
Return on assets-9.1%
Each USD of equity lost 15 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+2.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.7%
+2.2%
+2.3%
+1.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+81.7%
Change, 10 years—
The share count grew 82% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 57.1M
total assets, end of FY2025
Total assetsUSD 57.1M
EquityUSD 37.0M
CashUSD 10.7M
Gross debtUSD 8.8M
Net debtUSD -1.9M
Current ratio3.98×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.1
0.1
Operating income $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.15
−0.03
−0.37
−1.31
−3.83
−0.41
−0.56
−0.61
−0.51
−0.39
−0.29
−0.52
−1.48
−2.65
−1.21
−0.16
−0.37
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−15.3
−1.8
−47.7
−224.5
−178.0
−113.4
−143.4
−106.7
−60.4
−34.4
−22.0
−61.6
·
−1304.4
−87.9
−9.0
−18.8
Shares out B
0.04
0.03
0.03
0.01
0.01
0.09
0.07
0.06
0.05
0.05
0.05
0.05
0.04
0.02
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed